BAY 60-6583 is an agonist that targets the immunosuppressive adenosine A2b receptor, and it has been reported that activating the adenosine A2b receptor results in anti-inflammatory effects, like creating a tumor-promoting microenvironment, supporting tumor metastasis, and inducing immunosuppressive cells (Allard et al., 2016; Gao and Jacobson, 2019). This evidence concerns the gene ADORA2B and neoplasm.